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Abstract
Introduction: The Dependence Scale (DS) was designed to measure dependence on others among patients with Alzheimer’s
disease (AD). The objectives of this research were primarily to strengthen the psychometric evidence for the use of the DS in AD
studies. Methods: Patients with mild to moderately severe AD were examined in 3 study databases. Within each data set,
internal consistency, validity, and responsiveness were examined, and structural equation models were fit. Results: The DS has
strong psychometric properties. The DS scores differed significantly across known groups and demonstrated moderate to strong
correlations with measures hypothesized to be related to dependence (|r|  .31). Structural equation modeling supported the
validity of the DS concept. An anchor-based DS responder definition to interpret a treatment benefit over time was identified.
Discussion: The DS is a reliable, valid, and interpretable measure of dependence associated with AD and is shown to be related
to—but provides information distinct from—cognition, functioning, and behavior.
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Introduction
Alzheimer’s disease (AD) is a progressive illness characterized
by early symptoms that include memory loss and impaired cog-
nition; later stages are characterized by behavioral distur-
bances.1,2 This constellation of cognitive, functional, and
behavioral impairment is what creates the need for assistance,3
resulting in substantial caregiver burden. AD accounts for two-
thirds of all dementia cases and affects 8% of people older than
65 years and 15% of people older than 85 years.4 The average
length of time between onset of AD and death is 8 to 10
years,5-7 and it is estimated that 2 to 4 million Americans and
over 30 million people worldwide have been affected by AD.4,8
Dependence on caregiver assistance is an important concept
in Alzheimer’s research.9,10 The Dependence Scale (DS) was
originally developed by Stern and colleagues11 to capture the
caregiver’s report of the level of dependence of patients with
AD based on the care needed. The DS items were adapted from
an older instrument developed by Gurland.12 Stern and col-
leagues11 sought to quantify the AD-associated disability in
social or occupational function in terms of its impact on the
patient and his or her family. They created a version of the DS
intended to improve on existing measures of functional capacity,
such as the Blessed Dementia Rating Scale (BDRS),13 by
focusing on the degree of dependence and the actual level of care
needed.11 Because of the focus on patient need rather than spe-
cific task performance ability, the authors addressed an unmet
area of AD measurement. It is important to emphasize that the
DS measures the need for caregiver assistance, not the actual
care received. There may be factors extraneous to AD that influ-
ence the actual care received, for example, lack of nursing home
beds or insurance coverage. In AD, dependence is defined as the
need for assistance from others, and the DS is intended to mea-
sure the need for required care that results from AD.11,14 The DS
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was designed to be administered by a trained interviewer to a
caregiver of a patient with probable AD.
The relationship between behavior and dependence is also
important to assess because troublesome behaviors such as
aggression and wandering can result in increased requirements
for caregiving.15,16 The importance of evaluating the interrela-
tionships of these variables is to establish that functioning,
behavior, and dependence are distinct end points. Furthermore,
although cognition is the primary deficit in the AD process,
understanding how cognitive decline affects behavior, func-
tioning, and dependence can help to provide a more compre-
hensive understanding of the impact of the disease and how
it progresses. Cognitive deficits, including primarily memory
impairment, deficits in executive functioning, or confusion,
causing significant impairment in functioning is a central part
of the diagnostic criteria for AD.17 Functioning refers to how
well a person can perform the tasks required to maintain inde-
pendence in the community.
Modeling of the relationships among cognition, functioning,
behavior, dependence, and related variables has been previ-
ously reported. Cohen and Neumann18 reviewed 13 economic
models, a number of which incorporate cognition and function-
ing as predictors of disease outcome. In addition, 1 model by
Kinosian et al19 incorporated cognition, functioning, and beha-
vior in its modeling of disease progression. Murman et al20
modeled the relationships among cognition, neuropsychiatric
symptoms, parkinsonism, and medical comorbidities as predic-
tors of dependence and in turn societal direct costs. In this
model, cognition was a stronger predictor of dependency than
neuropsychiatric symptoms but was not a significant predictor
of societal direct costs, whereas neuropsychiatric symptoms
were significant predictors of societal direct costs.
Previous investigations have evaluated the reliability and
validity of the DS. For example, Stern and colleagues evaluated
the inter-rater reliability of the DS and found an intraclass cor-
relation of .90, indicating excellent agreement between raters.
However, the Cronbach’s a measure of internal consistency
was lower at .66,11 albeit acceptably >.65.21 These authors also
found that dependence was a strong predictor of living situation
(P < .001) in a logistic regression model. McLaughlin and col-
leagues22 found that the DS was significantly related to
changes in a measure of behavior (neuropsychiatric inventory
[NPI]), a measure of functioning (dependence in AD [DAD]),
and a measure of cognition (Mini-Mental State Examination
[MMSE]), while not being associated with age. These authors
suggested that when predicting costs of AD, MMSE was insuf-
ficient, and that other parameters such as those measured by the
DS or the DAD ought to be included. Brickman and col-
leagues14 demonstrated that dependence changed over time
independently of changes in cognition and changes in self-
care as measured by the BDRS.
McLaughlin and colleagues22 found that the association
between behavior and cognition was weaker than that between
dependence and behavior, and Murman and colleagues20 found
that the association between neuropsychiatric symptoms (akin
to maladaptive behavior) and dependence was weaker than that
between cognition and dependence. Based on this evidence, it
was reasonable to expect that the association between behavior
and dependence might be weaker than that between cognition
or functioning anddependence.Weexpected that cognition, func-
tioning, and behavior would all be related to dependence and that
functioningwould show the strongest relationship to dependence.
The aim of this research was to document further evidence of
the psychometric properties of the DS with data from 3 separate
studies. The objectives of this article were to (1) evaluate the evi-
dence for the reliability and validity of the DS with a larger and
more comprehensive data set than previously used to evaluate
these properties of the DS; (2) use structural equation modeling
techniques to further explore the theoretical relationships among
dependence, cognition, function, and behavior; and (3) evaluate
the responsiveness of the DS to change over time and refine cri-
teria for clinical interpretation.
Methods
Participants
Theparticipants in this analysiswere drawn from3 independently
conducted studies: the Predictors study23,20, the Elan-Alzhei-
mer’s Immunotherapy Program-Study 901 (ELN-AIP-901) and
the Dependence in Alzheimer’s Disease in England (DADE)
study. These studieswere chosen as they all contained theDS and
measures of cognition, functioning, and behavior. The DADE
study was cross-sectional, while the Predictors study and 901
study had a longitudinal component. Only patients with AD and
a baseline MMSE 10 were selected for these analyses, as the
analyses focused on the mild to moderately severe range of AD.
Predictors Study
The Predictors I study enrolled 238 participants in the early
stages of AD.24 The Predictors II study enrolled 225 partici-
pants beginning in 1997 using the same criteria that were used
to enroll Predictors I; these 2 studies were combined for the
current analysis and are referred to simply as the Predictors
study (n ¼ 460; 2 patients were missing baseline MMSE and
1 had MMSE <10). The purpose of the Predictors study was
to examine the predictors of disease progression in patients
who met the National Institute of Neurological and Communi-
cative Diseases (NINCDS) criteria for probable AD and who
demonstrated mild cognitive impairment (MCI) with a score
of10 on a converted MMSE score, based on a linear transfor-
mation of the modified MMSE (mMMS25).
The DADE Study
The DADE study was a cross-sectional observational study
designed to evaluate a classification model of people with
AD based on ‘‘dependence on others’’ and to determine the
relationship between dependence and cost of care in a UK set-
ting. The DADE study enrolled 249 patients with a diagnosis of
mild, moderate, and severe probable or possible AD according
to NINCDS/AD and Related Disorders Association (ADRDA)
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criteria. However, for the analyses in this article, only mild,
moderate, and moderately severe patients with AD (MMSE
 10; n ¼ 172) were included.
The ELN-AIP-901 Study
The 901 study enrolled 341 total patients (196 AD, 70 MCI,
and 75 healthy volunteers). The primary objective of the study
was to examine the psychometric properties of the neuropsy-
chological test battery (NTB) and the 9 individual NTB subt-
ests in patients with mild to moderate AD and to correlate
the NTB with other neurocognitive and functional assessments,
among them the DS. The analysis includes only 166 patients
with AD and at least 1 DS measurement.
The demographics and some clinical variables for the
patients in the Predictors, DADE, and 901 studies are presented
in Table 1. The Predictors study was the only study for the DS
with 18 months of follow-up from baseline. In the 901 study,
the DS was introduced partway through the study. As a result,
the 901 study had DS assessments starting at week 26 (n ¼ 95)
and at week 52 (n¼ 140) and week 78 (n¼ 134), resulting in a
maximum 12-month duration between assessments and no
baseline. The cross-sectional analyses using the 901 study data
in this report used the week 78 data as there were more patients
with follow-up DS scores at that time point. The 172 DADE
study participants’ mean age (79.9 years) was 5.3 years (95%
confidence interval [CI]: 3.5-7.0) older than the 460 Predictors
study patients at baseline (74.6 years), and 4.7 years (95% CI:
2.6-6.7) older than the 166 patients from the 901 study. The
gender distribution was almost evenly split in DADE, with a
higher proportion of females in the 901 study (44%-56% at
week 78) and 40% male to 60% female in the Predictors study.
The patients in the 901 study were predominantly white
(approximately 95% at each time point). Race was not recorded
in the DADE or the Predictors studies. In the DADE study, the
patients’ mean MMSE at baseline (18.4) was 2.5 points (95%
CI: 1.8-3.3) worse than the 460 Predictors patients at baseline
(20.9), and 3.3 points (95% CI: 2.4-4.2) worse than the 196
patients from the 901 study at baseline (21.7).
Measures
The following measures of cognition, behavior, and function-
ing were collected in each study: for cognition, the mMMS
(Predictors), MMSE (DADE), and AD Assessment Scale–cog-
nitive subscale (ADAS-Cog; ELN-AIP-901); for maladaptive
behavior, the Columbia University Scale of Psychopathology
in AD (CUSPAD; Predictors) and NPI (DADE and ELN-
Table 1. Demographic Summary of Predictors, DADE, and ELN-AIP-901 Studies (AD Group Only).
Predictors DADE
901 AD group
Baseline Week 26 Week 52 Week 78
N ¼ 460 N ¼ 172 N ¼ 95 N ¼ 140 N ¼ 134
Age, years
Mean (SD) 74.6 (8.8) 79.9 (8.0) 74.7 (6.9) 75.4 (6.3) 75.1 (6.9)
[range] [49–99] [53–102] [53–86] [57–86] [53–86]
Age group, years, n (%)
50–60 35 (7.6%) 6 (3.5%) 4 (4.2%) 4 (2.9%) 7 (5.2%)
61–70 90 (19.6%) 14 (8.2%) 18 (18.9%) 25 (17.9%) 24 (17.9%)
71–80 221 (48.1%) 63 (36.8%) 56 (58.9%) 80 (57.1%) 74 (55.2%)
>80 113 (24.6%) 88 (51.5%) 17 (17.9%) 31 (22.1%) 29 (21.6%)
Sex, n (%)
Male 185 (40.2%) 86 (50.6%) 41 (43.2%) 60 (42.9%) 59 (44.0%)
Female 275 (59.8%) 84 (49.4%) 54 (56.8%) 80 (57.1%) 75 (56.0%)
Race, n (%)
White 91 (95.8%) 134 (95.7%) 127 (94.8%)
Black or African American 3 (3.2%) 4 (2.9%) 5 (3.7%)
Asian 1 (1.1%) 2 (1.4%) 2 (1.5%)
Other 0 0 0
Duration of Alzheimer’s disease
Mean (SD) 5.4 (3.9) 3.4 (2.9) 3.2 (2.6) 3.4 (2.7)
[range] [0.3–16.0] [0.1–15.8] [0.0–15.8] [0.0–15.8]
MMSE score at baseline, N (%)
Mean (SD) 20.9 (3.1) 18.4 (4.6) 21.6 (3.5) 21.7 (3.6) 21.9 (3.6)
[range] [13–30] [10–29] [14–28] [14–30] [15–30]
MMSE score at baseline, N (%)
Mild, >22 169 (36.7%) 37 (21.5%) 41 (43.2%) 63 (45.0%) 64 (47.8%)
Moderate, 16–22 286 (62.2%) 86 (50.0%) 53 (55.8%) 75 (53.6%) 69 (51.5%)
Moderately severe, 10–15 5 (1.1%) 49 (28.5%) 1 (1.1%) 2 (1.4%) 1 (0.8%)
Abbreviations: AD, Alzheimer’s disease; DADE, Dependence in Alzheimer’s Disease in England; SD, standard deviation.
740 American Journal of Alzheimer’s Disease & Other Dementias® 28(8)
AIP-901); and for functioning, the BDRS (Predictors) and the
DAD (DADE and ELN-AIP-901).
Dependence Scale. The DS instrument has 2 parts. Part I, which
is used in outcome assessments, is comprised of 13 items. The
response scale for these 13 items is ‘‘yes/no’’ except the first 2
items that are graded ‘‘no/occasionally/frequently.’’ Part I is
scored from 0 to 15. Part II evaluates Equivalent Institutional
Care (EIC) and is not used in the DS scoring. There are 3 EIC
levels: limited home care, adult home, and health-related facil-
ity. The definition refers to the level of care required, not neces-
sarily to the actual placement, as some patients may receive
around-the-clock nursing care at home. In some analyses (spec-
ified in the tables), an imputation algorithm was used for part I
of the DS if an item was missing, in order to compute the total
score. The algorithm was based on the logic of the scale. For
example, if a patient did not need support for a higher function-
ing item such as household chores, it was assumed they would
not need support for the items that followed it in the scale, such
as needing to be watched or kept company when awake.
The BDRS was originally developed in 1968 by Blessed and
colleagues to explore the link between cerebral pathology
(changes in brain tissue) and severe mental decline in the elderly
patients.13 The BDRS consists of 22 total items assessing func-
tional changes in performing everyday activities (8 items),
changes in habits (3 items), and changes in personality, interest,
and drive (11 items). These items are rated by close relatives or
friends of the patients, and ratings are based on behavioral obser-
vations over the preceding 6 months. Overall scores for part I
range from 0 (normal) to 28 (extreme incapacity).26
The NPI is used to assess behavioral and psychological
symptoms in patients with dementia. The NPI takes approxi-
mately 10 minutes for the clinician to complete a caregiver
interview and covers 12 domains: delusions, hallucinations,
dysphoria, anxiety, agitation/aggression, euphoria, disinhibi-
tion, irritability/ability, apathy, aberrant motor behavior, sleep,
and eating. If a symptom is present, it is scored on a 4-point fre-
quency scale and a 5-point severity scale, with the product of
these scores ranging between 0 and 20.27
The CUSPAD is a short semistructured rating scale that a
clinician or research technician can administer to an informant.
The frame of inquiry is the month before examination. For the
current analysis, the dichotomous categories (present/absent)
of delusion (paranoid, misidentification, somatic, and abandon-
ment), hallucination (visual, auditory, tactile, and olfactory),
and illusion were summed into a behavioral symptoms score
ranging from 0 to 3.28
The ADAS-Cog is a widely used multi-item cognitive
functioning instrument that consists of 11 items measuring
the disturbances of memory, language praxis, attention, and
other cognitive abilities, which are considered to be the core
symptoms of AD.29 The ADAS-Cog score ranges from 0 to
70, with a higher score from baseline indicating decline in
cognition.
The MMSE is a widely used, clinician-administered screen-
ing tool for cognitive function in patients with dementia, scored
from 0 to 30, with higher scores indicating greater cognitive
functioning.30
The DAD is a 40-item functional measurement question-
naire that was designed to evaluate the cognitive processes of
initiation, planning, organization, and performance of both
instrumental and basic activities of daily living (ADLs) in
patients with AD or other dementias. In a caregiver interview,
the DAD contains 4 subdomains (hygiene, dressing, conti-
nence, and eating), assessing 17 basic ADLs, and 6 subdomains
(meal preparation, telephoning, going on an outing, finance and
correspondence, medications, and leisure and housework)
assessing 23 instrumental ADLs. Higher scores on the DAD
scale represent fewer disabilities in performing ADLs, and
lower values indicate increased disabilities in performing these
activities, with total scores ranging from 0 (most severe) to 100
(without disabilities).31
Data Analysis
Internal consistency reliability of the DS was evaluated in all 3
studies using Cronbach’s a. Validity was evaluated by examining
patterns of convergent and divergent correlations between the DS
and measures of cognition (MMSE and ADAS-Cog), function
(DAD and BDRS), and behavior (CUSPAD and NPI)—all the
measures of cognition, functioning, and behavior that were
included in the structural equationmodels. Known-groups validity
of the DS was evaluated through comparing mean scores in differ-
ent study subgroups defined by MMSE scores and by EIC levels.
Mild AD was defined as MMSE between 22 and 26, inclusive;
moderate AD was 16 and 21; and moderately severe AD defined
as 10 and 15.30 In the Predictors Study where the mMMS was
used, a conversion formula25 was applied: MMSE ¼ 0.495 
mMMSþ 1.495. For the validity analyses, data from baseline and
18months from the Predictors studywere used, but only data from
the week 78 visit in the 901 study.
To aid in the interpretation of the correlation matrices pre-
sented in the tables, for convergent validity, the DS, BDRS,
NPI, CUSPAD, and ADAS-Cog are scored in the same direc-
tion, with the MMSE and DAD scored in the opposite direc-
tion. For scales scored in the same direction, strong positive
correlations (>.50) provide evidence of convergent validity,
while for scales scored in opposite directions, strong negative
correlations provided evidence of convergent validity. Diver-
gent validity is demonstrated when scales show weak or non-
significant correlations (eg, <|.30|).
Path models using structural equation modeling techniques
in each of the 3 studies evaluated the relationships among
dependence, cognition, functioning, and behavior. All path
coefficients were standardized, and indirect effects were also
output. Specifically, the analysis was evaluating the extent to
which cognition and behavior had a direct effect on depen-
dence, or whether these effects were mediated by functioning
in fully saturated models. Mplus v6.12 software was used to
conduct these analyses.
To develop guidelines for interpretation of change over an
18-month time span, analyses were conducted using the
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Predictors study database. The magnitude of change over time
was evaluated by comparing the mean DS scores in stable sub-
groups with those of patients demonstrating a worsening in
their setting defined by EIC change categories to derive an
anchor-based responder definition.
Results
Table 2 provides the evidence for the internal consistency of
the DS in all 3 studies. These reliability estimates were remark-
ably consistent at approximately .72 to .81, exceeding the .70
threshold for group comparisons.32
Table 3 illustrates the pattern of convergent and divergent
validity between the DS and several other measures. These
cross-sectional correlations reveal a pattern of strong correla-
tions (|r| > .5) between the DS and measures of functioning
(DAD), moderate correlations (.3 > |r| < .5) with cognition
(MMSE) and dementia severity (Clinical Dementia Rating
Scale Sum of Boxes [CDR-SB]), and relatively weaker correla-
tions with the measure of behavior (NPI).
Known-groups validity was evaluated by comparing the DS
mean scores in subgroups created byMMSE cut points and EIC
status. Statistically significant overall and pairwise compari-
sons for mean scores classified by EIC status, MMSE cut
points, and the expanded MMSE severity groupings were
observed (Table 4 presents the mean scores by EIC status, and
Table 5 presents the mean scores by MMSE groups). The
means were all in the expected directions, with the DS scores
being lowest in the EIC level limited home care group, ranging
to highest in the health care facility group, with intermediate
mean scores in the assisted living group. The DS mean score
similarly increased across MMSE subgroups, indicating greater
dependence, on average, in more severely impaired patients.
Table 6 presents known-groups validity results for the Predic-
tors study at baseline and 18 months.
The first analysis of the theoretical model depicting relation-
ships among cognition, behavior, functioning, and dependence is
based on data from the Predictors study (Figure 1). The direct
effect of behavior as measured by the CUSPAD on DS was not
significant (standardized regression coefficient¼ .005); the total
CUSPAD effect (.192) was essentially completely mediated
through functioning as measured by the BDRS. The direct
(.183) and indirect (.074) effects of cognition (as measured
by the mMMS) on DS were both statistically significant, as was
the total effect (.257). The overall R2 for the DS in this model
is .398, which indicates that 39.8% of the variation in DS scores
was explained by mMMS, CUSPAD, and BDRS scores.
Figure 2 presents the path model using data from the DADE
study. This model, using MMSE to measure cognition, NPI to
measure behavior, and the DAD to measure functioning (3 dif-
ferentmeasures than in the Predictors study shown in Figure 1),
illustrated a set of relationships similar to the Predictors study
model. There was no statistically significant direct effect of
behavior on dependence. The standardized total NPI effect
(.145) was primarily mediated through functioning (.119);
both the direct effect of cognition on dependence (.140) and
the indirect effect (.298) were statistically significant. Taken
together,MMSE, NPI, andDAD scores explained 54.1% of the
variance of the DS scores. Themodel in Figure 3 is based on the
ELN-AIP-901 study and uses ADAS-Cog, DAD, and NPI as
the measures of cognition, functioning, and behavior, respec-
tively, along with the DS. In this model, behavior had a signif-
icant direct effect on dependence (path coefficient ¼ .237),
unlike the Predictors and DADE studies (path coefficients ¼
.005 and .026, respectively), with a marginally statistically
significant mediated effect through functioning (indirect effect
¼ .082 vs .197 and .119). The total behavior effect (.320) was
primarily a direct effect, whereas the total behavior effect was
primarily mediated through functioning for Predictors and
DADE. The total effect of cognition on dependence (.497) was
primarily mediated through functioning (.378), similar to the
DADE model. As in the Predictors and DADE studies, the
overall R2 for dependence was substantial, explaining 63.6%
of the DS score variance.
Table 2. Internal Consistency Reliability Estimates for DS Data Sets.
Study and time point Cronbach’s aa
Predictors study
Baseline (n ¼ 452) .72
Month 18 (n ¼ 327) .81
ELN-AIP-901
Week 26 (n ¼ 95) .75
Week 52 (n ¼ 140) .76
Week 78 (n ¼ 134) .78
DADE study
Baseline (n ¼ 159) .74
Abbreviation: DS, Dependence Scale; DADE, dependence in Alzheimer’s
disease in England.
a Patients with any missing items are excluded from this calculation.
Table 3. Pearson Correlations Between the DS and Other PRO
Study Measures in the Predictors Study at Baseline (n ¼ 431), 901
Study at Week 26 (n ¼ 91) and Week 78 (n ¼ 132), and DADE Study
at Baseline (n ¼ 151).a
Predictors DADE 901 901




MMSE .47 .53 .55
ADAS-Cog .42 .54
CDR-SB .64
DAD .72 .77 .74
NPI .21 .51 .38
Abbreviations: BDRS, Blessed Dementia Rating Scale; CUSPAD, Columbia
University Scale of Psychopathology in Alzheimer’s disease; MMSE, Mini-Mental
State Examination; mMMS, modified MMSE; ADAS-Cog, Alzheimer’s Disease
Assessment Scale–cognitive subscale; CDR-SB, Clinical Dementia Rating Scale
Sum of Boxes; DS, Dependence Scale; DAD, Dependence in Alzheimer’s dis-
ease; DADE, Dependence in Alzheimer’s Disease in England; NPI, neuropsy-
chiatric inventory; PRO, patient-reported outcome.
a All Ps < .0001.
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Todemonstrate the ability of theDS todetect change, themean
DS scoreswere calculated based onEIC change status for the Pre-
dictors study. As shown in Table 7, those who stayed in their own
homes during the 18months had amean increase of 1.12 points in
their DS scores. For patients who maintained their EIC status
(adult home/assisted living to adult home/assisted living or
Table 4. Comparison of Mean DS Scores Across Equivalent Institutional Care Status in the ELN-AIP-901 Study AD Arm at Week 26 (n ¼ 93),
Week 52 (n ¼ 138), and Week 78 (n ¼ 132); DADE Study at Baseline (n ¼ 168); and Predictors at Baseline (n ¼ 452) and Month 18 (n ¼ 325).a
Study
Limited home care Adult home Health-related facility
Mean (SE; 95% CI; n) Mean (SE; 95% CI; n) Mean (SE; 95% CI; n)
ELN-AIP-901, week 26 4.30 (0.29; 3.71-4.88; 54) 6.81 (0.36; 6.10-7.52; 37)b 8.50 (1.53; 5.46-11.54; 2)c,d
ELN-AIP-901, week 52 4.32 (0.23; 3.85-4.78; 88) 6.74 (0.34; 6.08-7.41; 43)b 9.86 (0.83; 8.21-11.50; 7)e,f
ELN-AIP-901, week 78 4.77 (0.26; 4.25-5.29; 78) 6.91 (0.34; 6.23-7.59; 46)b 10.25 (0.82; 8.62-11.88; 8)e,g
DADE 5.22 (0.32; 4.58-5.85; 55) 7.13 (0.20;6.73-7.53;99)b 10.64 (0.41; 9.75-11.54; 14)e,h
Predictors, BL 4.17 (0.11; 3.95-4.38; 266) 6.67 (0.15; 6.38-6.96; 146)b 7.50 (0.28; 6.94-8.06; 40)e,i
Predictors, month 18 4.79 (0.22; 4.35-5.22; 84) 7.14 (0.16; 6.83-7.46; 155)b 9.87 (0.22; 9.45-10.30; 86)e,h
Abbreviations: AD, Alzheimer’s Disease; BL, baseline; CI, confidence interval; DS, Dependence Scale; DADE, Dependence in AD in England; GLM, generalized
linear model; SE, standard error.
a GLM with all within-study pairwise comparisons.
b Limited home care vs adult home, P < .0001.
c Limited home care vs facility, P < .05.
d Adult home vs facility, ns.
e Limited home care vs facility, P < .0001.
f Adult home vs facility, P < .001.
g Adult home vs facility, P < .01.
h Adult home vs facility, P < .0001.
i Adult home vs facility, P < .05.
Table 5. Comparison of Mean DS Scores With MMSE Severity Groups in the ELN-AIP-901 Study AD Arm atWeek 26 (n¼ 95), Week 52 (n¼





16  MMSE < 22
Moderately severe dementia,
10  MMSE < 16
Mean (SE; 95% CI; n) Mean (SE; 95% CI; n) Mean (SE; 95% CI; n)
ELN-AIP-901, week 26 4.26 (0.34; 3.58-4.94; 42) 5.73 (0.36; 5.01-6.45; 37)b 7.50 (0.55; 6.40-8.60; 16)c,d
ELN-AIP-901, week 52 3.26 (0.32; 3.34-4.56; 55) 5.66 (0.29; 5.08-6.24; 64)b 7.85 (0.53; 6.81-8.89; 20)c,e
ELN-AIP-901, week 78) 4.15 (0.34; 3.48-4.83; 52) 6.26 (0.33; 5.60-6.92; 54)b 7.27 (0.52; 6.24-8.31; 22)c,f
DADE (n ¼ 49) 5.22 (0.32; 4.57-5.88; 49) 6.74 (0.27; 6.21-7.27; 73)g 8.44 (0.31; 7.82-9.06; 48)c,d
Predictors, BL 4.48 (0.17; 4.16-4.81; 165) 5.77 (0.14; 5.50-6.05; 237)h 7.67 (1.23; 5.24-10.09; 3)e,i
Predictors, month 18 5.29 (0.29; 4.72-5.86; 55) 6.77 (0.22; 6.34-7.20; 100)b 8.12 (0.26; 7.60-8.63; 68)c,f
Abbreviations: AD, Alzheimer’s disease; BL, baseline; CI, confidence interval; DS, Dependence Scale; DADE, Dependence in AD in England; GLM, generalized
linear model; MMSE, Mini-Mental State Examination; SE, standard error.
a GLM with all within-study pairwise comparisons.
b Mild vs moderate, P < .001.
c Mild vs moderately Severe, P < .0001.
d Moderate vs moderately Severe, P < .01.
e Moderate vs moderately Severe, ns.
f Moderate vs moderately Severe, P < .001.
g Mild vs moderate, P < .01.
h Mild vs moderate, P < .0001.
i Mild vs moderately severe, P < .05.
Table 6.Mean Scores for the DS by Equivalent Institutional Care Status at Baseline and 18 Months Follow-Up, Restricted to Respondents at 18
Months in the Predictors Study.
Equivalent institutional care baseline Mean N SD Equivalent institutional care 18-months Mean N SD
Limited home care 4.25 196 1.74 Limited home care 4.82 82 1.89
Adult home/assisted living 6.67 95 1.75 Adult home 7.21 153 1.62
Health-related facility 7.61 28 1.91 Health-related facility 9.91 85 2.53
Total 5.25 320 2.20 Total 7.31 320 1.97
Abbreviations: DS, Dependence Scale; SD, standard deviation.
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institution to institution) over 18months, themean change scores
were approximately1point at 18months. For patientswhomoved
to settings that required higher levels of care (home to adult home/
assisted living, home to institution, or adult home/assisted living
to health-related facility), the DSmean change scores were much
larger, ranging from2.31 to 5.8 point increases. Themean change
score differences reported in Table 7 were statistically significant
at the P < .001 level. In addition, pairwise comparisons between
the 3 EIC change situations beginning with home placement and
the 2 EIC changes representing stability or decline that beginwith
adult home/assisted living EIC status were also significant. The
bottom 2 rows of Table 7 report the EIC change status and mean
score changes for very few (n ¼ 7) respondents with improved
EIC status. The effect sizes included in the table indicate that a
change of 1 point is comparable to an effect size of about 0.5, and
the effect sizes associatedwith a 2-point changeweremuch larger
(1.5 and more)
In summary, a change of only about 1 point was indicative of
the following successful outcomes: remaining in one’s own home
with limited assistance or remaining in adult home status and not
progressing to living in a health care facility in the Predictors
study data. However, a change of 2 points or greater was associ-
ated with a clinically meaningful decline in the data set. There-
fore, it was determined that a DS score increase in 1 point
corresponds with stability in care setting over the 18-month time
span and demonstrates an interpretable treatment benefit in AD.
Finally, the change score correlations between changes in the
DS and changes in measures of cognition, function, and behavior
were evaluated in the 901 study (Tables 8) and the Predictors
Study (Table 9). These results indicated that in spite of strong cor-
relations between functioning and dependence cross-sectionally,
the change score correlationswere generally onlymoderately cor-
related, providing further evidence that dependence and function-
ing as measured by the DS and DAD are different concepts.
Figure 1. Fully saturated model of dependence in all participants in the Predictors study. The circled values pointing to Blessed and DS are
unexplained variance ¼ 1-R2. Blessed indicates Blessed Dementia Rating Scale; DS, Dependence Scale.
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Discussion
The analyses presented in this report provide substantial evi-
dence supporting the reliability, validity, and interpretability
of the DS. The DS is quickly completed by a caregiver and is
readily understood.33 Cronbach’s a, an index of internal consis-
tency reliability, was above .70 in all 3 studies, a well-accepted
threshold for establishing reliability. The pattern of convergent
validity correlations shows a stronger relationship between the
DS and measures of functioning, such as the DAD, particularly
when compared with the correlation with the behavioral mea-
sure, the NPI. The correlations with the cognition measures
were almost as strong as with the functioning measures.
The evaluation of differences in mean scores across study
population subgroups (known-groups validity) provides further
evidence for the validity of the DS. For example, DS scores were
statistically significantly different in the Predictors study when
comparing patients with an EIC status of ‘‘limited home care,’’
‘‘adult home/assisted living,’’ and ‘‘health-related facility,’’ with
scores increasing in severity across the subgroups. Similarly,
when comparing across subgroups defined byMMSE status, that
is, mild, moderate, moderate to severe, and severe, statistically
significantly different mean scores were observed between each
category, with mean scores indicating greater dependence corre-
sponding with increasing cognitive impairment.
The path models further refine the understanding of the the-
oretical relationships among cognition, functioning, behavior,
and dependence relative to the correlational analyses and
allowed testing of not only direct but also indirect and mediat-
ing effects. First, the path coefficients of 3 models were very
similar, and about 50% of the variance in dependence, as
reflected by the r2 statistics, was explained by cognition, func-
tioning, and behavior across all 3 studies. Second, the total
effect of behavior on dependence was weaker than the total
effect of cognition on dependence in all models, with its direct
effects on dependence very close to 0 and not statistically sig-
nificant in 2 of the 3 studies. In the ELN-AIP-901 study, there
was a significant effect of behavior on dependence that was not
Figure 2. Theoretical model of cognition, behavior, functioning, and dependence: DADE study saturated model. The circled values pointing
to DAD and DS are unexplained variance ¼ 1  R2. DAD indicates Dependence in Alzheimer’s disease; DADE, Dependence in Alzheimer’s
Disease in England; DS, Dependence Scale.
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Figure 3. Theoretical model of cognition, behavior, functioning, and dependence: ELN-AIP-901 study saturated model, AD Arm, week 78. AD
indicates Alzheimer’s disease.
Table 7. Mean Change Scores in the DS by Change in Care Settings (EIC Status) Over 18 Months in the Predictors Study.a
Change care needs group N Mean DS change score SE bl_SD SES
Home to home 77 1.12 0.25 1.78 0.63
Home to adult home/assisted living 89 2.31 0.19 1.54 1.50
Home to health-related facility 31 5.81 0.58 1.93 3.01
Adult home/assisted living to adult home/assisted living 62 0.89 0.26 1.72 0.52
Adult home/assisted living to health-related facility 28 3.11 0.39 1.66 1.87
Health-related facility to health-related facility 26 1.35 0.54 1.95 0.69
Health-related facility to adult home/assisted living 2b 2.00 1.00 0.71 2.82
Adult home/assisted living to home 5b 0.00 0.95 1.95 0.00
Abbreviations: DS, Dependence Scale; EIC, Equivalent Institutional Care; SE, standard error of the mean change score; bl_SD, standard deviation of the baseline
score; SES, standardized effect size of mean change, mean change/bl_SD.
a N ¼ 320.
b Sizes of groups of patients who go from more to less restrictive care are too small to be used to draw conclusions.
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mediated through functioning. This difference in the direct
effect of behavior on dependence could be an artifact of period
and/or study cohort effects. This pattern of results, showing that
dependence, cognition, and functioning are related but distinct
concepts, supports the importance of the DS as an end point in
AD clinical trials in adding unique information to the evalua-
tion of a therapy. Indeed, the DS measures a concept, the need
for caregiver assistance, which is distinct from functioning, as
measured by the DAD. The statistically weaker effects of beha-
vior in these models suggest that behavior is not as good a pre-
dictor of need for this assistance, as operationalized by the DS,
as functioning and cognition are.
What constitutes an important change over time on the DS?
First, it is essential to understand that prevention of further
deterioration remains an important goal of treatment. As Table
7 indicates, for example, participants who remained home, who
remained in adult homes, or who remained in health care facil-
ities showed about a 1 point change. This was associated with
an effect size of about 0.5, which is ordinarily a meaningful
benchmark. However, over 18 months, those who deteriorated
only 1 point on the DS remained at the same level in terms of
EIC, leading to the conclusion that a deterioration of only 1
point is still a positive outcome. However, those patients who
showed a difference of 2 points or more were likely to show
deterioration in their EIC status. For example, in the Predictors
study, the transition from home to assisted living was associ-
ated with a 2.3-point mean change and the transition from
home to health care facility was associated with a mean change
of 5.8 points on the DS.
The use of different measures of cognition, functioning, and
behavior across the 3 studies (eg, the CUSPAD in the Predictors
study and the NPI in DADE and 901 studies) might be seen as a
potential limitation. However, the similarity of findings in spite
of the heterogeneity of measures suggests robustness in the
relationships observed. These analyses add to a growing body
of literature supporting the validity of the DS. The DS has been
shown in another recent study to be moderately to strongly cor-
related with the CDR-SB,34 the Zarit caregiver burden scale, the
DAD, and the Resource Utilization in Dementia (RUD-lite).35
Additional work has evaluated the relationship of the DS to
important economic outcomes, including risk of hospitalization,
increased risk of nursing home admission, and increased risk of
use of antipsychotics,10 and it has been used in economic mod-
eling.22 Further support for the link between the DS and care-
giver burden has been provided by the work of Lacey and
colleagues9 in an analysis of the 901 data. That study concluded
that as care recipient dependence increased, caregivers reported
increase in daily schedule disruption, greater lack of family sup-
port, and increased time as a caregiver. Lacey36 analyzed the
association between DS and caregiver measures of subjective
burden and health status/utility and observed that caregiver bur-
den increased as dependence on the caregiver increased. The
analyses controlled for patient and caregiver age, patient gender,
patient stage of cognitive impairment and number of ADLs
limitations, behavioral problems, and country. Finally, Lacey
and colleagues37 studied the relationship between dependence
with clinical measures of cognition, function, and behavior
changes over time and concluded that the relationships between
dependence and other clinical measures of cognition, function-
ing, and behavior can be observed over time.
In summary, this article provides convincing empirical evi-
dence of the reliability, validity, and responsiveness to change
in the DS across 3 independently conducted studies. The DS
has been shown to be reliable and consistently correlated with
Table 8. Pearson Correlations Between Change in DS and Other PRO Study Measures in the ELN-AIP-901 Study AD Arm From Week 26 to
Week 78.a
Correlations at week 26
(P value)
Correlations at week 78
(P value)
Correlations of change scores from
week 26 to week 78 (P value)
MMSE .49 (<.0001) .51 (<.0001) .28 (.0227)
ADAS-Cog .31 (.0128) .49 (<.0001) .14 (.2661)
DAD .73 (<.0001) .76 (<.0001) .35 (.0045)
NPI .52 (<.0001) .46 (<.0001) .31 (.0130)
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, AD Assessment Scale–cognitive subscale; DAD, Dependence in AD; DS, Dependence Scale; MMSE,
Mini-Mental State Examination; PRO, patient-reported outcome; NPI, neuropsychiatric inventory.
a N ¼ 65.
Table 9. Pearson Correlations Between Change in DS and Other PRO Study Measures in the Predictors Study From Baseline to Month 18.a
Correlations at baseline
(P value)
Correlations at month 18
(P value)
Correlations of change scores from
baseline to month 18 (P value)
MMSE .32 (<.0001) .49 (<.0001) .42 (<.0001)
BDRS .59 (<.0001) .69 (<.0001) .54 (<.0001)
CUSPAD .21 (.0006) .27 (<.0001) .19 (.0013)
Abbreviations: BDRS, Blessed Dementia Rating Scale; CUSPAD, Columbia University Scale of Psychopathology in Alzheimer’s disease; DS, Dependence Scale;
MMSE, Mini-Mental State Examination; PRO, patient-reported outcome.
a N ¼ 277.
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cognition, functioning, and behavior, important variables for
defining, evaluating, and understanding the effects of AD on
patients and their families. Moreover, through structural equa-
tion modeling, it was shown that dependence is a concept that is
related to cognition, function, and behavior but also distinct
from these domains. Approximately 50% of the variance in
dependence was predicted by the 3 measures, and the effect
of cognition on dependence was not fully mediated by func-
tioning, suggesting they are different concepts. Analyses of
changes in the DS suggest that a 1-point change over time is
associated with a positive outcome, whereas a change of 2 or
more points represents a clinically meaningful deterioration
in Predictors study data. The results presented in this article
should increase the confidence of researchers and regulators
in using and interpreting the DS as an end point in clinical trials
for mild to moderate AD.
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